In Phase C, participants will receive ABBV-744 and oral navitoclax. In Phase D, contributors will get ABBV-744 and ruxolitinib. Members will get treatment right until disease progression or perhaps the individuals are unable to tolerate the study drugs. There may be higher treatment burden for participants On this trial as https://abbv-744brd4inhibitioninc79013.dailyhitblog.com/37402106/5-easy-facts-about-abbv-744-brd4-inhibitor-mechanism-of-action-described